Synthesis and Evaluation of Carbohydrate Vaccine Adjuvants
碳水化合物疫苗佐剂的合成与评价
基本信息
- 批准号:10642889
- 负责人:
- 金额:$ 63.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-10 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAntibody ResponseAntigen-Presenting CellsAntigensApplications GrantsAzidesB-LymphocytesBiodistributionCD8-Positive T-LymphocytesCarbohydratesCell MaturationChemistryClinicalClinical TrialsCommunicable DiseasesDevelopmentEthersEvaluationExhibitsFluoresceinFluoridesGalactoseGenerationsGlucoseGlycosidesGoalsHigh Pressure Liquid ChromatographyHumanHydrogen BondingHydroxyl RadicalHypocotylImmune responseImmunityImmunologicsImmunologyIn VitroIowaLabelLinkMediatingMedicinal PlantsMetabolicMethodsNatural ProductsNatural SourceOligosaccharidesPlasmaProcessProductionQS21RegulationRespiratory Syncytial Virus VaccinesRoleSafetySaponinsSourceSoyasapogenolSoyasaponinStructureStructure-Activity RelationshipT cell responseTherapeuticToxic effectUniversitiesVaccinationVaccine AdjuvantVaccinesVariantaluminum sulfatecarbenecatalystchemical synthesisclinical applicationclinically relevantcombatcost effectivecytokineglycosylationimmunogenicityimprovedin vivomouse modelmultidisciplinarynovelnovel vaccinespreclinical evaluationscreeningsoysuccesstoolvaccinology
项目摘要
PROJECT SUMMARY
The success of vaccination requires the generation of a strong immune response to the
inoculated antigens in order to provide long-term protective immunity against many infectious
diseases. To achieve this goal often requires the addition of vaccine adjuvants, substances that
a substance that boosts the body’s immune response to the vaccine. However, there are only a
few human vaccine adjuvants with an extensive safety record and minimal toxicity approved for
clinical use. At presence, more studies are needed to identify novel adjuvants that not only
significantly enhance the immune response for a particular vaccine, but also must be minimally
toxic and maximally safe for clinical use. In efforts to discover novel vaccine adjuvants, an in
vivo screening of forty-seven saponins from medicinal plants for their immunostimulatory and
hemolytic activities has led to the discovery of new exciting vaccine adjuvants. Among forty-
seven saponins evaluated, soyasaponins have emerged as the most potent adjuvants. These
newly-discovered carbohydrates exhibited a significantly enhanced adjuvant activity with almost
negligible toxicity when directly compared to QS-21 which has emerged as a vaccine adjuvant in
numerous clinical trials. However, obtaining them from natural sources is a complicated process
of extraction and purification that result in the production of minute. As a result, isolation of
soyasaponins is economically unfeasible and unsustainable if sufficient quantities are required
for immunological studies and clinical applications. Since FDA has strict regulations regarding to
the purity and quality of adjuvants for use in human, a synthetic source must be developed for
soyasaponins to be utilized as clinically relevant adjuvants. The objective of this proposal will
address these challenges through the chemical synthesis for procuring sufficient quantities of
soyasaponins in pure form. This effort will deliver well-defined soyasaponins without batch-to-
batch variation and provide tools for studies of their roles as vaccine adjuvants and exploration
of structure-adjuvant potency profiles for the discovery of non-natural soyasaponin improved
adjuvants.
项目总结
疫苗接种的成功需要对疫苗产生强烈的免疫反应
接种抗原以提供对许多传染性疾病的长期保护性免疫
疾病。为了实现这一目标,通常需要添加疫苗佐剂,即
一种能增强人体对疫苗的免疫反应的物质。然而,只有一个
很少有安全记录广泛且毒性最小的人类疫苗佐剂被批准用于
临床应用。目前,需要更多的研究来确定新的佐剂,不仅是
显著增强对特定疫苗的免疫应答,但也必须最低限度
有毒,临床使用最安全。在努力发现新的疫苗佐剂的过程中,一种
从药用植物中筛选出47个具有免疫刺激作用的皂苷类化合物
溶血活性导致了新的令人兴奋的疫苗佐剂的发现。在四十个人中-
对七种皂苷进行了评估,大豆皂苷已成为最有效的佐剂。这些
新发现的碳水化合物显示出显著增强的佐剂活性,几乎
直接与QS-21相比,毒性可以忽略不计,QS-21已成为
无数的临床试验。然而,从自然资源中获取它们是一个复杂的过程
提取和纯化的结果导致分钟的生产。因此,隔离
如果需要足够的数量,大豆皂苷在经济上是不可行的,也是不可持续的
用于免疫学研究和临床应用。由于FDA对以下方面有严格的规定
人类使用的佐剂的纯度和质量,必须开发一种合成来源来
大豆皂苷将被用作临床相关佐剂。这项提议的目标将是
通过化学合成来解决这些挑战,以获得足够数量的
纯种形式的大豆皂苷。这一努力将提供定义明确的大豆皂苷,而不需要批量到
批量变异,并为研究它们作为疫苗佐剂的作用和探索提供工具
发现改良非天然大豆皂苷的结构佐剂效价谱
佐剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hien M Nguyen其他文献
Hien M Nguyen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hien M Nguyen', 18)}}的其他基金
Development of Catalytic Glycosylations and Biologically Important Glycosaminoglycans
催化糖基化和具有生物学重要性的糖胺聚糖的发展
- 批准号:
10622180 - 财政年份:2023
- 资助金额:
$ 63.57万 - 项目类别:
Synthesis and Evaluation of Carbohydrate Vaccine Adjuvants
碳水化合物疫苗佐剂的合成与评价
- 批准号:
10538831 - 财政年份:2022
- 资助金额:
$ 63.57万 - 项目类别:
Strategies for Expedited Synthesis of Sulfated Aminoglycans
硫酸化氨基聚糖的快速合成策略
- 批准号:
10371884 - 财政年份:2020
- 资助金额:
$ 63.57万 - 项目类别:
Strategies for Expedited Synthesis of Sulfated Aminoglycans
硫酸化氨基聚糖的快速合成策略
- 批准号:
10594458 - 财政年份:2020
- 资助金额:
$ 63.57万 - 项目类别:
Catalytic Methods for Stereoselective 1,2-Cis Glycosylation
立体选择性 1,2-顺式糖基化的催化方法
- 批准号:
9163857 - 财政年份:2016
- 资助金额:
$ 63.57万 - 项目类别:
Synthesis and Evaluation of Zwitterionic Carbohydrate Immunostimulants
两性离子碳水化合物免疫增强剂的合成与评价
- 批准号:
9109179 - 财政年份:2016
- 资助金额:
$ 63.57万 - 项目类别:
Tailoring Structures of Sulfated Oligosaccharides for Modulating Heparanase Activity
用于调节乙酰肝素酶活性的硫酸低聚糖的剪裁结构
- 批准号:
10164799 - 财政年份:2012
- 资助金额:
$ 63.57万 - 项目类别:
Tailoring Structures of Sulfated Oligosaccharides for Modulating Heparanase Activity
用于调节乙酰肝素酶活性的硫酸低聚糖的剪裁结构
- 批准号:
9816301 - 财政年份:2012
- 资助金额:
$ 63.57万 - 项目类别:
相似海外基金
Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study
描述 SARS-CoV-2 抗体反应及其与患者因素的关联:参与 GENCOV 研究的参与者的血清学分析
- 批准号:
495256 - 财政年份:2023
- 资助金额:
$ 63.57万 - 项目类别:
Understanding the human antibody response to a malaria transmission-blocking vaccine
了解人类抗体对疟疾传播阻断疫苗的反应
- 批准号:
MR/X009491/1 - 财政年份:2023
- 资助金额:
$ 63.57万 - 项目类别:
Research Grant
Probing the role of peptidoglycan modification in the antibody response to Staphylococcus aureus
探讨肽聚糖修饰在金黄色葡萄球菌抗体反应中的作用
- 批准号:
10549646 - 财政年份:2023
- 资助金额:
$ 63.57万 - 项目类别:
Identification of the antigenic targets of the clonal antibody response to Clostridioides difficile infection
鉴定针对艰难梭菌感染的克隆抗体反应的抗原靶点
- 批准号:
10742376 - 财政年份:2023
- 资助金额:
$ 63.57万 - 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
- 批准号:
10688292 - 财政年份:2022
- 资助金额:
$ 63.57万 - 项目类别:
Molecular dissection of IgA antibody response by developing monoclonal IgA antibodies from nasal mucosa of mice
通过从小鼠鼻粘膜中开发单克隆 IgA 抗体对 IgA 抗体反应进行分子剖析
- 批准号:
22H02875 - 财政年份:2022
- 资助金额:
$ 63.57万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
- 批准号:
10634694 - 财政年份:2022
- 资助金额:
$ 63.57万 - 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
- 批准号:
10514498 - 财政年份:2022
- 资助金额:
$ 63.57万 - 项目类别:
Factors related to antibody response of COVID-19 vaccines: with focusing on metabolomics
与 COVID-19 疫苗抗体反应相关的因素:重点关注代谢组学
- 批准号:
22H03334 - 财政年份:2022
- 资助金额:
$ 63.57万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
- 批准号:
10527979 - 财政年份:2022
- 资助金额:
$ 63.57万 - 项目类别: